Mereo BioPharma Group plc
MREO
$2.30
$0.177.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -88.89% | -88.89% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -88.89% | -88.89% | -- | -- |
| Cost of Revenue | -- | -110.98% | -121.66% | 323.74% | 315.45% |
| Gross Profit | -- | -80.45% | -77.34% | 441.96% | 521.23% |
| SG&A Expenses | 43.46% | 4.52% | -7.59% | -35.82% | -32.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.10% | -7.64% | -18.11% | -31.48% | -33.38% |
| Operating Income | -68.46% | -14.32% | 1.57% | 50.70% | 51.32% |
| Income Before Tax | -44.18% | -53.63% | -10.92% | 39.53% | 34.38% |
| Income Tax Expenses | -- | -734.84% | -496.13% | -62.44% | 35.18% |
| Earnings from Continuing Operations | -46.78% | -51.43% | -8.91% | 40.29% | 34.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.78% | -51.43% | -8.91% | 40.29% | 34.37% |
| EBIT | -68.46% | -14.32% | 1.57% | 50.70% | 51.32% |
| EBITDA | -69.86% | -14.07% | 2.30% | 51.45% | 51.79% |
| EPS Basic | -31.05% | -32.81% | 3.17% | 47.14% | 40.22% |
| Normalized Basic EPS | -28.78% | -34.86% | 1.36% | 46.50% | 40.29% |
| EPS Diluted | -31.05% | -28.50% | 8.34% | 49.30% | 42.57% |
| Normalized Diluted EPS | -28.78% | -34.86% | 1.36% | 46.50% | 40.29% |
| Average Basic Shares Outstanding | 12.14% | 12.59% | 11.99% | 10.63% | 9.30% |
| Average Diluted Shares Outstanding | 12.14% | 12.59% | 11.99% | 10.63% | 9.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |